ISP To Increase Global Prices an Additional 10%

ISP To Increase Global Prices an Additional 10%

Senior Vice President Global Pharma & Beverage
Phone: +49 2236 9649 269

Steve Olsen
Senior Vice President
Global Performance Chemicals
Phone: +1.973.628.3368

James Mish
Senior Vice President
Global Global Personal Care
Phone: +1.1.973.628.3203  Eileen Mascari
Resource Advantage Group, Inc.
Phone: +1.973.882.1313
Fax:+1.973.575.1720
E-mail:[email protected] 
 
 
Wayne, N.J. - May 2, 2011 - International Specialty Products Inc. (ISP) will increase global prices for polymers, vinyl monomers, emollients, emulsifiers, preservatives and encapsulates 10% effective June 1, 2011, or as contracts allow.

This increase applies to products sold into the personal care, pharmaceutical, oral care, beverage, performance chemicals and agricultural markets. This price increase is in addition to the 10% increase that was previously announced effective February 1, 2011. This additional price increase is necessary due to continued material and energy cost escalation.

 
 
*****END*****
About ISP
International Specialty Products Inc. (ISP) is a leading global supplier of specialty chemicals and performance enhancing products for a wide variety of personal care, pharmaceutical, food, beverage and industrial applications. ISP produces more than 500 specialty chemicals, which it markets and sells worldwide. The company's headquarters is located in Wayne, New Jersey, USA.

 
This press release may contain "forward-looking statements" within the meaning of the federal securities laws and, as such, concerns matters that are not historical facts. These statements are based on our current expectations and assumptions, which are subject to a number of risks and uncertainties that could cause the actual results to differ materially from those anticipated, projected or implied. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Copyright © 2009 International Specialty Products. All Rights Reserved 

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.